Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)

Next Previous
X
Search
Trial Profile

Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Anterior uveitis; Axial spondyloarthritis
  • Focus Therapeutic Use
  • Acronyms C-VIEW
  • Sponsors UCB Biopharma

    • Most Recent Events

    • 15 Jun 2024 Results assessing anterior uveitis flares rate in patients with axSpA who are at high risk of recurrent uveitis when treated with the PEGylated Fc-free TNF inhibitor certolizumab pegol (CZP) compared with standard non-biologic care presented at the 25th Annual Congress of the European League Against Rheumatism
    • 15 Nov 2023 Results assessing efficacy certolizumab pegol (CZP) compared with standard non-biologic care, presented at the ACR Convergence 2023.
    • 05 Jun 2021 Results assessing the 2-year outcomes and impact of certolizumab pegol treatment on acute anterior uveitis in patients with active ankylosing spondylitis, presented at the 22nd Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top